By Mauro Orru

Bayer AG said Thursday that it would develop a next-generation sequencing-based companion diagnostic for Vitrakvi along with Colorado-based biotechnology company ArcherDX.

The German pharmaceutical and chemical company didn't disclose financial details, but said its partnership with ArcherDX is aimed at expanding patient access to genomic testing.

Next-generation sequencing-based companion diagnostic testing seeks to release molecular information from patients' tumor genomes to subsequently guide treatment decisions for cancer therapies, Bayer said.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

May 14, 2020 07:45 ET (11:45 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Bayer